The euro is heading for a fifth consecutive week of decline, but signs of weakening selling pressure are emerging.
智通财经2026/10/09 04:06(1) On Friday, the euro is heading for its fifth consecutive weekly decline. However, as the French bond market stabilizes and falling US Treasury yields temper the dollar’s rally, the sustained selling pressure on the euro is beginning to show signs of easing. (2) On Monday, the euro briefly fell to 1.1161 against the US dollar, hitting a 17-month low before rebounding; this week it remains down 0.1%, with a cumulative loss of over 3% over the past five weeks. (3) Matt Simpson, senior analyst at StoneX in Brisbane, said: "I think the current market move now looks a little overdone. The euro typically only experiences two or three major swings a year, and this is one of those... but the bearish momentum is waning, so trading at current lows should be approached with particular caution." (4) Vishnu Varathan, Head of Asia Pacific Macroeconomics and Strategy at Mizuho Securities, stated that the dollar is currently “in a precarious position of dominance,” with its strength partly owing to the weak performance of both the euro and the yen.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium; IPO price falls to lower range at $14.
According to Zhitong Finance APP, TRex Bio Inc., an early-stage biotechnology company focused on autoimmune and inflammatory diseases, raised 116.7 million dollars through its IPO, pricing at the lower end of its indicated range.
EBA strengthens risk review of European banks’ sovereign bonds: risk exposure remains controllable
(1) The head of the European Banking Authority (EBA) stated that European banking regulators are conducting additional reviews regarding the risks associated with the trillions of euros in sovereign bond portfolios held by banks. (2) According to the official, as the yields on government bonds in some core European countries have soared to multi-year highs, the government debt investment portfolios held by banks require enhanced monitoring. (3) Currently, the relevant risk exposures still appear to be "within controllable ranges." (4) The net interest income generated from bonds has largely offset the impact of declining bond prices on the economic value of banks' equity. (5) He said, "So far, we have not seen banks suffer significant losses as a result of the current situation, and we are confident that regulators are taking the necessary responsive measures."
Small molecule biotechnology company Iambic Therapeutics (IAM.US) sets IPO price at $15-17 per share, plans to raise $150 millions
According to Jinse Finance, it has been reported that Iambic Therapeutics (IAM.US), a biotechnology company developing small-molecule anti-cancer therapies based on its self-developed artificial intelligence (AI) platform and currently in Phase I clinical trials, announced its IPO terms on Thursday. The San Diego, California-based company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to $17 per share. Some investors have already expressed their intention to purchase $60 million worth of shares in this offering, accounting for 40% of the deal. At the midpoint of the proposed price range, Iambic Therapeutics would have a fully diluted market value of $809 million.
3D printing materials supplier Amaero (AMRO.US) restarts US IPO with fundraising amount plunging 60% to $20 million
According to information from Zhitong Finance APP, Amaero (AMRO.US), a producer specializing in titanium and refractory metal powders for 3D printing in the defense and aerospace sectors, has resumed its initial public offering (IPO) plans in the United States as of Thursday, submitting new documents to the U.S. Securities and Exchange Commission (SEC) revealing a reduced offering size. The company is currently listed on the Australian Securities Exchange and had previously attempted a cross-listing on Nasdaq in September, but postponed the listing due to unfavorable market conditions. The exact timing of the IPO remains undetermined.
Crypto prices
More
